Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback